Top-Rated StocksTop-RatedNASDAQ:NTRA Natera (NTRA) Stock Price, News & Analysis $118.82 +0.01 (+0.01%) (As of 02:31 PM ET) Add Compare Share Share Today's Range$118.00▼$120.8050-Day Range$97.75▼$123.9852-Week Range$36.90▼$124.83Volume361,271 shsAverage Volume1.39 million shsMarket Capitalization$14.59 billionP/E RatioN/ADividend YieldN/APrice Target$120.07 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Natera MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1.3% Upside$120.07 Price TargetShort InterestHealthy6.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 15 Articles This WeekInsider TradingSelling Shares$10.43 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.43) to ($1.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.64 out of 5 starsMedical Sector712th out of 940 stocksMedical Laboratories Industry16th out of 19 stocks 2.5 Analyst's Opinion Consensus RatingNatera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNatera has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Natera's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.21% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Natera has recently decreased by 9.72%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NTRA. Previous Next 2.6 News and Social Media Coverage News SentimentNatera has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Natera this week, compared to 7 articles on an average week.Search Interest19 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 46% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Natera to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,425,404.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Natera is held by insiders.Percentage Held by Institutions99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Natera's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($2.43) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -38.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -38.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 18.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Natera's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Angel PublishingWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.Discover how to receive your FIRST "Stimulus Stipends" payment for up to $7,882 here. About Natera Stock (NASDAQ:NTRA)Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Read More NTRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NTRA Stock News HeadlinesAugust 20, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) CEO Sells $663,874.53 in StockAugust 17, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) Insider Jonathan Sheena Sells 12,000 SharesAugust 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…August 15, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) Insider Sells $307,314.00 in StockAugust 1, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) CEO Sells $419,712.68 in StockAugust 1, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) Insider Sells $108,627.89 in StockAugust 29 at 5:13 AM | americanbankingnews.comNatera (NASDAQ:NTRA) Downgraded to Sell at StockNews.comAugust 29 at 4:11 AM | americanbankingnews.comCanaccord Genuity Group Raises Natera (NASDAQ:NTRA) Price Target to $145.00August 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…August 29 at 3:13 AM | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) Receives $119.07 Consensus Target Price from BrokeragesAugust 29 at 12:45 AM | msn.comNatera, Inc. (NTRA): Among Morgan Stanley’s Highest Conviction StocksAugust 28 at 7:22 PM | finance.yahoo.comNatera to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 28 at 12:29 AM | msn.comNatera, Inc. (NTRA): Among Morgan Stanley's Highest Conviction StocksAugust 21, 2024 | americanbankingnews.comNatera (NASDAQ:NTRA) Upgraded to "Hold" at StockNews.comAugust 20, 2024 | fool.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtAugust 19, 2024 | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 5,583 SharesAugust 16, 2024 | uk.investing.comNatera co-founder Sheena Jonathan sells over $300k in company stockAugust 15, 2024 | seekingalpha.comNatera: Focus On Signatera And H1 2024 ResultsSee More Headlines Company Calendar Last Earnings8/08/2024Today8/29/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:NTRA CUSIPN/A CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees3,293Year FoundedN/APrice Target and Rating Average Stock Price Target$120.07 High Stock Price Target$150.00 Low Stock Price Target$70.00 Potential Upside/Downside+0.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($3.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-434,800,000.00 Net Margins-30.24% Pretax Margin-30.19% Return on Equity-49.72% Return on Assets-26.08% Debt Debt-to-Equity Ratio0.36 Current Ratio4.12 Quick Ratio3.98 Sales & Book Value Annual Sales$1.36 billion Price / Sales10.74 Cash FlowN/A Price / Cash FlowN/A Book Value$6.37 per share Price / Book18.68Miscellaneous Outstanding Shares122,803,000Free Float113,470,000Market Cap$14.61 billion OptionableOptionable Beta1.48 Key ExecutivesDr. Matthew Rabinowitz Ph.D. (Age 51)Co-Founder & Executive Chairman Comp: $441.58kMr. Steven Leonard Chapman (Age 45)CEO & Director Comp: $1.15MMr. Michael B. Brophy M.B.A. (Age 44)Chief Financial Officer Comp: $611.35kMr. Daniel Rabinowitz L.L.M. (Age 55)Secretary & Chief Legal Officer Comp: $566.03kMr. John FeskoPresident & Chief Business OfficerMr. Jonathan Sheena M.Eng. (Age 51)Co-Founder & Director Comp: $293.91kMs. Olesya A. Anisimova CPAChief Accounting OfficerMr. Rishi KackerChief Technology OfficerMr. Eric A. EvansChief Scientific OfficerMr. Jerry DiffleyChief Compliance & Privacy OfficerMore ExecutivesKey CompetitorsQuest DiagnosticsNYSE:DGXFresenius Medical CareNYSE:FMSPACS GroupNYSE:PACSOption Care HealthNASDAQ:OPCHSotera HealthNASDAQ:SHCView All CompetitorsInsiders & InstitutionsMaven Securities LTDBought 2,000 shares on 8/29/2024Ownership: 0.002%Cetera Investment AdvisersSold 2,889 shares on 8/22/2024Ownership: 0.014%Truist Financial CorpSold 3,115 shares on 8/21/2024Ownership: 0.033%HWG Holdings LPBought 3,009 shares on 8/19/2024Ownership: 0.002%Quarry LPBought 190 shares on 8/16/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions NTRA Stock Analysis - Frequently Asked Questions How have NTRA shares performed this year? Natera's stock was trading at $62.64 at the start of the year. Since then, NTRA shares have increased by 89.3% and is now trading at $118.57. View the best growth stocks for 2024 here. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) announced its earnings results on Thursday, August, 8th. The medical research company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.39. Natera's revenue for the quarter was up 58.1% on a year-over-year basis. What is Steve Chapman's approval rating as Natera's CEO? 158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. When did Natera IPO? Natera (NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Natera's top institutional investors include Fred Alger Management LLC (4.29%), Farallon Capital Management LLC (3.63%), Massachusetts Financial Services Co. MA (1.95%) and Duquesne Family Office LLC (1.61%). Insiders that own company stock include Matthew Rabinowitz, Jonathan Sheena, Daniel Rabinowitz, Steven Leonard Chapman, Solomon Moshkevich, John Fesko, Michael Burkes Brophy, Herm Rosenman, James Healy, Gail Boxer Marcus, Todd C Cozzens, Rowan E Chapman, Robert Alan Schueren and Roelof Botha. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Natera investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV) and Aegean Marine Petroleum Network (ANW). This page (NASDAQ:NTRA) was last updated on 8/29/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinThe Bitcoin Halving ignited the 2024 boom, and altcoins are primed to SKYROCKET. Last year we tipped off ou...Crypto 101 Media | SponsoredWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredFirst Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Natera, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Natera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
